Domainex Supports Sitryx's MTHFD2 Programme Resulting in the Nomination of Development Candidate, SIT047

Domainex is delighted to have supported Sitryx’s MTHFD2 programme which resulted in SIT047, a novel, oral inhibitor, progressing to clinical development for psoriatic arthritis. Over the course of the programme, Domainex established a close partnership with the Sitryx team and this collaborative approach was essential to the success of the project. Working together we overcame significant technical hurdles with drug design, balancing selectivity and mitochondrial permeability. Structural biology was key to the project, with the Domainex team developing a soak system and producing numerous high-resolution structures. The novel screening cascade we developed was essential to demonstrate biochemical and cellular selectivity as well as mechanism of action. We congratulate Sitryx on the achievement of reaching this milestone.